TSZ ISABEL WONG: Open Payments
NPI 1144626508 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$11,650 in 262 payments from 49 companies in 2025. Trend: 2023 $5,983 · 2024 $5,757 · 2025 $11,650
Food & beverage: $5,961Consulting: $3,957Speaker / faculty: $945Education: $565Travel & lodging: $222
| Company | Payments | Amount |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 20 | $5,453 |
| Janssen Biotech, Inc. | 20 | $563 |
| Astellas Pharma US Inc | 11 | $482 |
| BeOne Medicines USA, Inc. | 12 | $354 |
| AstraZeneca Pharmaceuticals LP | 15 | $318 |
| ABBVIE INC. | 15 | $314 |
| Rigel Pharmaceuticals, Inc. | 8 | $310 |
| Merck Sharp & Dohme LLC | 12 | $261 |
| Novartis Pharmaceuticals Corporation | 10 | $260 |
| Incyte Corporation | 9 | $251 |
Products named: PYRUKYND, ERLEADA, TEVIMBRA, TAVALISSE, KEYTRUDA, TAGRISSO, REBLOZYL, Lenvima.
Industry payments across NY — which companies pay providers there.
